Good morning, everyone, and how are you today? We are quite busy scrambling to play catchup after a quick day away from the usual routine. The coffee kettle is fired up, though, as we concoct several cups of stimulation — we continue to favor blueberry cobbler this week — and start tackling our to-do list. Speaking of which, here are a few items of interest to help you manage your own agenda. So time to get cracking. Hope your journey is a smooth one and please do continue to keep in touch …

Democratic presidential candidates are threatening to take a controversial step that even the Obama administration rejected to lower drug prices without congressional approval, The Hill writes. The idea, known as march-in rights, involves invoking an obscure section of a 1980 law to break the patent on a drug when it is priced too high. The authority to use it has never been invoked before, but Democratic presidential candidates are increasingly embracing the idea and touting it as a concrete action they could take if they win the White House.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy